Ratings Astellas Pharma Inc. OTC Markets

Equities

ALPMY

US04623U1025

Market Closed - OTC Markets Other stock markets 01:29:59 06/06/2024 am IST			5-day change	1st Jan Change
10.23 ^USD	+1.69%		+6.01%	-14.03%

03/06	US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	MT
31/05	U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company is one of the best yield companies with high dividend expectations.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 149.6 times its estimated earnings per share for the ongoing year.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ASTELLAS PHARMA INC.	-14.03%	18.3B	-
ELI LILLY AND COMPANY	+42.69%	749B	C+
NOVO NORDISK A/S	+38.62%	605B	B
JOHNSON & JOHNSON	-6.87%	351B	C+
MERCK & CO., INC.	+18.74%	328B	B-
ABBVIE INC.	+6.76%	292B	C+
ASTRAZENECA PLC	+18.68%	248B	B+
ROCHE HOLDING AG	-2.49%	214B	A+
NOVARTIS AG	+11.11%	216B	B-
PFIZER, INC.	+2.64%	167B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes